ClinicalTrials.gg
CompletedNCT02631954Updated Mar 18, 2020Results posted

Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

A Phase 1 interventional study of Vorico Injection 200mg(Voriconazole) and Vfend®(Voriconazole) IV 200mg in Aspergillus Infections, Candida Infections and Fungal Infections, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-18.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.

Enrollment
8th of 17
24 · median 24
Started
2015
the only one that year
Phase 1
3 of 17
none open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
Chong Kun Dang Pharmaceutical

Among the 17 studies testing voriconazole in Aspergillosis, this one is the 8th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1, and was the 16th registered.

Aspergillosis

134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.

Browse Aspergillosis studies →

Open to participants now

None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →

About voriconazole

Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing voriconazole in Aspergillosis as a file.
02

Study summary

Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

Read the detailed description

To healthy volunteers subjects of twenty four(24), following treatments are administered dosing in each period injected wash-out period is a minimum of 7days. Treatment A(Test Drug): Vorico Injection 200mg(Voriconazole) for Single Dose Treatment B(Reference Drug): Vfend® IV 200mg for Single Dose Pharmacokinetic blood samples are collected up to 24hrs.

Safety and pharmacokinetic are assessed.

03

Conditions studied

  • Aspergillus Infections
  • Candida Infections
  • Fungal Infections
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A healthy person whose age is in between 19 to 55 during the screening tests
  2. Whose weight is more than 55 kg, is over 18.5 and under 30.0 during the screening test. (BMI (kg/m2) = weight (kg) / {height (m)}2)
  3. Who is completely informed and understand about this clinical trial, voluntarily participating it, and signed to follow the given instructions
  4. Who is proven to fit into the clinical trial following by physical examination, (electrocardiogram), clinical laboratory test, medical examination
  5. Who agreed to do during testing

    • A male who did not have vasectomy has to follow the clinically proven contraceptive methods* listed under, and who agreed not to donate sperm during the test

      * Clinically proven contraceptive method: intrauterine device (ex. Lippes Loop, Minera), chemical contraceptive (spermicides) for use with physical contraceptive method (males or females), contraceptive implants (ex. Implanon), tubal ligation or laparoscopy (common methods of tubal ligation)

    • A woman of childbearing age who agreed on constant use of a medically disproven Dual Protection method** and spermicides except hormonal contraceptive, and who also agreed not to breastfeed.

      • A Dual Protection method: use of condoms, the Intrauterine Contraceptive Device, the diaphragm, the cervical cap, in the case where a sexual partner had vasectomy over 3 months ago (from the date of initial screening) or a sexual partner had been medically diagnosed sterile.

Exclusion criteria

Exclusion Criteria:

  1. A person who has a history of cardiovascular, respiratory, liver, kidney, endocrine system, immune system, urinary system diseases, blood-tumor diseases, mental illness.
  2. Who has a history of reactions to antifungal drugs including voriconazole or similar series or other ingredients (aspirin, antibiotics, etc.)
  3. Who has genetics issues on galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption
  4. Who has a history of gastrointestinal disease (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (other than simple appendectomy and herniotomy)
  5. A person whose value includes > 440 msec, PR \< 110 msec or PR > 200 msec, QRS \< 60 msec or QRS > 110 msec after screening, or who show clinically significant opinion.
  6. Who falls under the following results

    1. , ALT are exceeded over 1.5x the
    2. Total is exceeded over 1.5x the upper limit of the normal range
  7. Who shows the vital sign values of more than 140 mmHg or less than 90 mmHg in systolic pressure or more than 100 mmHg or less than 60 mmHg in diastolic blood pressure
  8. Who has history of drug abuses or shows a positive result in the urinary drug screen
  9. Who took any prescribed drugs, medicinal plants within the 2 weeks before the first day of dosing or takes any over-the-counter drugs or vitamin supplements within 1 week (but, if other conditions are met, they can still participate in the clinical test through the researcher's judgment)
  10. Who took other drugs or bioequivalence drugs within 3 months before the first day of dosing
  11. Who participated in whole blood donation within 2 months before the first of dosing, or donations within 1 months. Who received blood a month before the first day of dosing
  12. Who constantly drinks alcohol (over 21 units/week, 1 unit = 10 g of pure alcohol) or cannot stop drinking alcohol during the clinical test.
  13. Who smokes more than 10 cigarettes per day, or who cannot quit smoking when hospitalized
  14. Who absorb caffeinated drinks (coffee, tea (black or green tea), soda, coffee flavored milk, energy drinks, etc.) or cannot stop absorbing them 24 hours before hospitalization until discharging
  15. Who takes drug metabolism drug like barbital drugs which inhibit or activate the metabolism or drugs, or who takes one of the following drugs: St. John's Wort, rifabutin, rifampicin, carbamazepine, phenobarbital, high-dose of ritonavir, terfenadine, astemizole, cisapride, pimozide, quinidine, sirolimus, ergot, alkaloid (ergotamine, dihydroergotamine), efavirenz
  16. Who was having foods (especially grapefruit or products contain grapefruit) that can influence the drug absorption, distribution, metabolism, and excretion within 7 days from the first day of dosage
  17. A woman who is pregnant, shows positive result in serum/urine test, or who is breastfeeding
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    TR Group

    Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg

    Drug: Vorico Injection 200mg(Voriconazole) · Drug: Vfend®(Voriconazole) IV 200mg

  • Experimental
    RT group

    Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)

    Drug: Vorico Injection 200mg(Voriconazole) · Drug: Vfend®(Voriconazole) IV 200mg

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax of Voriconazole

    The blood sampleing coleected from the subjects was analyzed and result was obtained.

    Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs

  2. AUCt of Voriconazole

    The blood sampleing coleected from the subjects was analyzed and result was obtained.

    Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs

Secondary outcomes

  1. Tmax of Voriconazole

    The blood sampleing coleected from the subjects was analyzed and result was obtained.

    Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs

  2. AUCinf of Voriconazole

    The blood sampleing coleected from the subjects was analyzed and result was obtained.

    Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs

  3. AUCt/AUCinf

    The blood sampleing coleected from the subjects was analyzed and result was obtained.

    Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs

  4. Kel (Elemination Rate Constant)

    The blood sampleing coleected from the subjects was analyzed and result was obtained.

    Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs

  5. t1/2

    The blood sampleing coleected from the subjects was analyzed and result was obtained.

    Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs

07

Results

Posted Mar 18, 2020

Participant flow

Participant flow — Overall Study
MilestoneTR GroupRT Group
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryCmax of Voriconazole

The blood sampleing coleected from the subjects was analyzed and result was obtained.

Time frame:
0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
Reported as:
Mean · ng/mL
Cmax of Voriconazole
ng/mLReferenceTest
Cmax of Voriconazole2433.7 ± 2456.91997.0 ± 406.2
PrimaryAUCt of Voriconazole

The blood sampleing coleected from the subjects was analyzed and result was obtained.

Time frame:
0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
Reported as:
Mean · hr*ng/mL
AUCt of Voriconazole
hr*ng/mLReferenceTest
AUCt of Voriconazole6966.17 ± 2856.107469.78 ± 3125.73
SecondaryTmax of Voriconazole

The blood sampleing coleected from the subjects was analyzed and result was obtained.

Time frame:
0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
Reported as:
Mean · hr
Tmax of Voriconazole
hrReferenceTest
Tmax of Voriconazole1.57 ± 0.031.58 ± 0.04
SecondaryAUCinf of Voriconazole

The blood sampleing coleected from the subjects was analyzed and result was obtained.

Time frame:
0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
Reported as:
Mean · hr*ng/mL
AUCinf of Voriconazole
hr*ng/mLReferenceTest
AUCinf of Voriconazole8159.24 ± 4905.058631.50 ± 4401.54
SecondaryAUCt/AUCinf

The blood sampleing coleected from the subjects was analyzed and result was obtained.

Time frame:
0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
Reported as:
Mean · Ratio
AUCt/AUCinf
RatioReferenceTest
AUCt/AUCinf0.94 ± 0.100.90 ± 0.09
SecondaryKel (Elemination Rate Constant)

The blood sampleing coleected from the subjects was analyzed and result was obtained.

Time frame:
0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
Reported as:
Mean · 1/hr
Kel (Elemination Rate Constant)
1/hrReferenceTest
Kel (Elemination Rate Constant)0.10 ± 0.030.10 ± 0.04
Secondaryt1/2

The blood sampleing coleected from the subjects was analyzed and result was obtained.

Time frame:
0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
Reported as:
Mean · hr
t1/2
hrReferenceTest
t1/28.42 ± 4.617.98 ± 2.92

Adverse events

Collected over 1 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reference0/23 (0%)0/23 (0%)21/23 (91.3%)
Test0/24 (0%)0/24 (0%)22/24 (91.7%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventReferenceTest
photophobiaEye disorders18/2321/24
dizzinessVascular disorders3/233/24
vision blurredEye disorders2/230/24
headacheNervous system disorders0/232/24
colour blindness acquiredEye disorders1/230/24
visual imparimentEye disorders1/231/24
white blood cells urine positiveInvestigations1/230/24
nasal congestionRespiratory, thoracic and mediastinal disorders1/230/24
epistaxisVascular disorders1/230/24
blood glucose increasedInvestigations0/231/24

Baseline characteristics

24 subejcts were used for baseline analysis.

Age, Categorical
Age, Categorical(Participants)TR GroupRT GroupTotal
<=18 years000
Between 18 and 65 years121224
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)TR GroupRT GroupTotal
Female000
Male121224
08

Study locations

1 site
  • Inha University Hospital
    Incheon, 22332, Korea, Republic of
09

References and documents

Publications

  • Cho SH, Kim CW, Nam MS. Pharmacokinetics and Safety of Two Voriconazole Formulations after Intravenous Infusion in Healthy Korean Volunteers. Infect Chemother. 2020 Jun;52(2):204-211. doi: 10.3947/ic.2020.52.2.204. Epub 2020 May 29. PubMed 32468741 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Oct 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2020, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2015
First posted
Dec 16, 2015
Start
Sep 2015
Primary completionActual
Oct 2015
CompletionActual
Nov 2015
Results first posted
Mar 18, 2020
Last update
Mar 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02631954
Responsible party
Sponsor
First posted
Dec 16, 2015
Start date
Sep 2015
Primary completion
Oct 2015
Completion
Nov 2015
Results posted
Mar 18, 2020
Last update
Mar 18, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion